Core Viewpoint - The investment philosophy of Duan Yongping emphasizes understanding the intrinsic value of a company beyond market fluctuations, as illustrated by the recent share reduction news from WuXi AppTec [1] Group 1: Shareholder Actions - On October 29, WuXi AppTec announced a plan for its actual controller to reduce shares by up to 2% of the total share capital through centralized bidding and/or block trading [1] - The market reacted strongly to the news, despite the reduction being relatively small and regulated, indicating a growing desensitization among investors regarding the negative perception of share reductions [1] Group 2: Company Performance - Since October 30, WuXi AppTec's stock has outperformed the market, even increasing by 1.19% during the share reduction period from November 20 to 25 [2] - WuXi AppTec has established a unique business model since its founding in 2000, focusing on assisting pharmaceutical companies in lowering development barriers and accelerating new drug launches [2] Group 3: Financial Metrics - Investors who held WuXi AppTec shares since its IPO have seen a return of 12.3 times by September this year, supported by a solid business model [3] - As of the first half of this year, WuXi AppTec's ongoing business orders have achieved a compound growth rate of 38% since 2018, nearing 60 billion [3] - By the third quarter of 2025, WuXi AppTec's revenue is projected to exceed 32.857 billion, with a year-on-year growth of 18.61% and an increase in net profit margin from 26.5% to 32.1% [3] Group 4: Shareholder Returns - WuXi AppTec's expected earnings per share in 2025 will be seven times that of its IPO, with a total of 20 billion allocated for cash dividends and share buybacks over the past seven years [4] - The company has implemented a nearly 7 billion shareholder return plan for 2025, which represents 72% of the net profit for 2024 [4] - For the first three quarters of 2025, WuXi AppTec's net profit attributable to shareholders reached 12.076 billion, reflecting an 84.84% year-on-year increase [4] Group 5: Long-term Belief - Achieving a 12-fold return over seven years requires a strong belief in the long-term value of the company and the power of belief itself [5]

Core Viewpoint - Nomura's report indicates that WuXi AppTec's strong R&D capabilities enable it to seize market opportunities, reaffirming a "Buy" rating and raising the target price from HKD 130.63 to HKD 132.8 [1] Group 1: Company Performance - As of the end of fiscal year 2025 (September), the company has undertaken a total of 3,430 projects, which is approximately three times the number in 2021 [1] - The breakdown of projects includes 2,889 in preclinical, 374 in Phase I, 87 in Phase II, 80 in Phase III, and commercial stages [1] - The total order backlog reached CNY 59.88 billion, with new orders signed in the third quarter increasing by 32% year-on-year to CNY 15.3 billion [1]

Core Viewpoint - The Hong Kong innovative drug concept stocks experienced a decline, with notable drops in several key companies [1] Company Performance - WuXi AppTec saw a decline of over 3% [1] - Innovent Biologics and Hansoh Pharmaceutical both dropped by more than 2% [1] - China National Pharmaceutical Group and CSPC Pharmaceutical Group fell by over 1% [1]

Core Viewpoint - WuXi AppTec (603259.SH) announced a significant change in shareholder equity, with a reduction of 11,827,898 shares, representing 0.40% of the total share capital as of the announcement date [1] Group 1: Shareholder Changes - The company received a notification regarding the reduction of shares held by certain shareholders from 547,539,294 shares to 535,711,396 shares, decreasing their ownership percentage from 18.35% to 17.95% [1][2] - The reduction in shareholding occurred between November 20, 2025, and November 25, 2025, with a weighted average price of 93.571 yuan per share during this period [2] - The total amount of shares sold by the shareholders amounted to approximately 1.107 billion yuan [2]

Core Viewpoint - The data indicates significant outflows of capital from various stocks, highlighting potential concerns regarding investor sentiment and market stability [1] Group 1: Major Stocks with Capital Outflows - WuXi AppTec experienced a capital outflow of 367 million yuan [1] - Huadian Technology saw an outflow of 298 million yuan [1] - Lezhi Group had a capital outflow of 254 million yuan [1] - Inspur Information faced an outflow of 248 million yuan [1] - Yongding Holdings recorded an outflow of 245 million yuan [1] - Tianhua New Energy experienced a capital outflow of 211 million yuan [1] - Changxin Bochuang had an outflow of 198 million yuan [1] - Hainan Ruize saw an outflow of 197 million yuan [1] - Sanjiang Shopping recorded a capital outflow of 185 million yuan [1] - Yaowang Technology faced an outflow of 183 million yuan [1] - Tianji Holdings had a capital outflow of 182 million yuan [1] - CATL experienced an outflow of 159 million yuan [1] - BlueFocus Communication Group saw an outflow of 152 million yuan [1] - Industrial and Commercial Bank of China recorded a capital outflow of 151 million yuan [1] - China Film faced an outflow of 148 million yuan [1] - Vanke A experienced a capital outflow of 147 million yuan [1] - Guofeng New Materials saw an outflow of 142 million yuan [1] - Shiji Information recorded a capital outflow of 142 million yuan [1] - Meilixin faced an outflow of 135 million yuan [1] - Zhongwen Online experienced a capital outflow of 134 million yuan [1]

格隆汇11月27日丨根据联交所最新权益披露资料显示，2025年11月21日，药明康德(02359.HK)获JPMorgan Chase & Co.以每股均价102.4881港元增持好仓 73.65万股，涉资约7548.34万港元。 增持后，JPMorgan Chase & Co.最新持好仓数目为25,720,236股，持好仓比例由4.89%上升至5.03%。 | 股份代號: | 02359 | | --- | --- | | 上市法國名稱: | 無錫藥明康德新藥開發股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 27/10/2025 - 27/11/2025 | | 麦格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | | 持有權益的股份數目 | 佔已發行的 有關事 | | --- | --- | --- | --- | --- | --- | --- | | | 份數目 | 原因 | | | | (請參閱上述 * 註解) 有投票權股 (日 / 月 | | | | | | | | 份自分比 | | | | | | | | 96 1 | ...

（文章来源：证券日报） 证券日报网讯 11月26日晚间，药明康德发布公告称，2025年11月26日，公司收到信息披露义务人发出 的通知，获知其于2025年11月20日至2025年11月25日通过集中竞价方式合计减持公司股份11，827，898 股，占本公告日公司总股本的0.40%。信息披露义务人及与实际控制人签署投票委托书的股东合计持有 公司股份数从547，539，294股减少至535，711，396股，持股比例从18.35%减少至17.95%，权益变动 触及1%刻度。 ...

智通财经APP获悉，香港联交所最新数据显示，11月21日，摩根大通增持药明康德(02359)73.6509万 股，每股作价102.4881港元，总金额约为7548.34万港元。增持后最新持股数目约为2572.02万股，持股 比例为5.03%。 ...

智通财经APP获悉，香港联交所最新数据显示，11月21日，摩根大通增持药明康德(02359)73.6509万 股，每股作价102.4881港元，总金额约为7548.34万港元。增持后最新持股数目约为2572.02万股，持股 比例为5.03%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年11月26日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-072 关于股东权益变动触及 1%刻度的提示性公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性陈 ...